Description

N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine (CAS No. 162012-67-1) is a high-purity quinazoline derivative designed for advanced research applications. This compound features a molecular formula of C₁₄H₇ClF₂N₄O₂ and a molecular weight of 336.68 g/mol, with a unique nitro-fluoro substitution pattern that enhances its reactivity and binding affinity. Its structural complexity makes it an ideal candidate for pharmaceutical development, particularly in kinase inhibition studies and targeted cancer therapies. The product is rigorously tested for purity (≥95% by HPLC) and stability, ensuring reliable performance in sensitive assays. Available in milligram to gram quantities, it is supplied in amber vials under inert atmosphere to prevent degradation.

Properties

• CAS Number: 162012-67-1
• Complexity: 441
• IUPAC Name: N-(3-chloro-4-fluoro-phenyl)-7-fluoro-6-nitro-quinazolin-4-amine
• InChI: InChI=1S/C14H7ClF2N4O2/c15-9-3-7(1-2-10(9)16)20-14-8-4-13(21(22)23)11(17)5-12(8)18-6-19-14/h1-6H,(H,18,19,20)
• InChI Key: CJOJDNRJDBWZKM-UHFFFAOYSA-N
• Exact Mass: 336.0225595
• Molecular Formula: C14H7ClF2N4O2
• Molecular Weight: 336.68
• SMILES: C1=CC(=C(C=C1NC2=NC=NC3=CC(=C(C=C32)[N+](=O)[O-])F)Cl)F
• Topological: 83.6
• Monoisotopic Mass: 336.0225595
• Synonyms: 162012-67-1, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine, DTXSID60442902, DTXCID60393723, 808-276-1, 4-QUINAZOLINAMINE, N-(3-CHLORO-4-FLUOROPHENYL)-7-FLUORO-6-NITRO-, 4-(3-Chloro-4-fluorophenylamino)-7-fluoro-6-nitroquninazoline, MFCD09998825, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-4-quinazolinamine, 4-[(3-chloro-4-fluorophenyl)amino]-7-fluoro-6-nitroquinazoline, (3-Chloro-4-fluoro-phenyl)-(7-fluoro-6-nitro-quinazolin-4-yl)-amine, C14H7ClF2N4O2, 4-(3-CHLORO-4-FLUOROPHENYLAMINO)-7-FLUORO-6-NITROQUINAZOLINE, CJOJDNRJDBWZKM-UHFFFAOYSA-N, N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitro-4-quinazolinamine; (3-Chloro-4-fluorophenyl)(7-fluoro-6-nitroquinazolin-4-yl)amine, N-(3-chloro-4-fluoro-phenyl)-7-fluoro-6-nitro-quinazolin-4-amine, SCHEMBL25241, BCP08568, CS-M0991, AKOS015917847, AKOS034830279, PB34506, AC-27054, AS-11445, SY028080, A3594, C3276, 4-(3-chloro-4-fluorophenyl)amino-6-nitro-7-fluoroquinazoline, 6-nitro-4-(3-chloro-4-fluorophenylamino)-7-fluoro-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-fluoro-6-nitro-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-fluoro-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-fluoroquinazoline, 4-[N-(3-Chloro-4-fluorophenyl)amino]-7-fluoro-6-nitroquinazoline, 4-Quinazolinamine,N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazoline-4-amine, (3-Chloro-4-fluoro-phenyl)-(7-fluoro-6-nitro-quinazoline-4-yl)-amine, (3-CHLORO-4-FLUOROPHENYL)(7-FLUORO-6-NITROQUINAZOLIN-4-YL)AMINE, 4-(3-CHLORO-4-FIUORO-PHENYLAMINO)-7-FLUORO-6-NITROQUNINAZOLINE, 4-(3-CHLORO-4-FLUORO-PHENYLAMINO)-7-FLUORO-6-NITROQUNINAZOLINE

Application

N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine is primarily utilized in medicinal chemistry as a key intermediate for synthesizing EGFR (Epidermal Growth Factor Receptor) inhibitors. Researchers employ this compound to investigate structure-activity relationships in tyrosine kinase inhibition, particularly for non-small cell lung cancer (NSCLC) therapeutics. Its nitro group allows for further functionalization via reduction or nucleophilic substitution, enabling diversification of quinazoline-based drug candidates.

Safety and Hazards

GHS Hazard Statements

• Not Classified
• Reported as not meeting GHS hazard criteria by 1 of 1 companies. For more detailed information, please visit ECHA C&L website.

Hazard Classes and Categories

• Not Classified

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.